Belarus Medical Device Risk Classes 1, 2a, 2b and 3

1. Key takeaways

Belarus classifies medical devices into four levels — 1, 2a, 2b and 3 — according to potential application risk; the devices are not divided into Class I/II/III, and the Roman numerals I/IIa/IIb/III are not the statutory notation. The classification rules originate in Decision No. 173 of the Board of the Eurasian Economic Commission of 22 December 2015, and in vitro diagnostic devices are likewise classified into four tiers under separate criteria.

2. Legal basis

3. Expert insights

Insight 1: the four-tier scheme is the union’s common language, which Belarus uses directly. In announcing № 211, the government press service used the expression medical devices of the low (first) potential risk level, corresponding exactly to Class 1 in the union classification rules. This shows that Belarus has not built a separate scheme for the basic concept of risk classification but keeps it aligned with the union — good news for companies preparing both the national and the union route, since a classification conclusion can be reused.

Insight 2: 1, 2a, 2b and 3 are not the same thing as Class I/II/III. Chinese-language materials often render Belarusian device classes as Class I, Class II and Class III, or as the Roman numerals I/IIa/IIb/III. GRZAN uses Class 1 / Class 2a / Class 2b / Class 3 consistently in this series, for two reasons: first, the statutory scheme has four tiers, not three; second, the Roman numerals are a rendering of the European notation, not the native expression of Belarusian and union documents. Uniform notation is not merely a formatting issue — it directly affects how a client understands which tier its product falls into.

Insight 3: IVD devices are classified separately and the criteria for general devices cannot be applied to them. The union classification rules set out separate criteria for in vitro diagnostic devices, covering both individual risk and risk to public health. If an IVD company mechanically applies the general criteria of contact duration and invasiveness, it can easily reach a wrong class conclusion, which in turn skews the direction of testing programs and clinical evidence preparation.

Insight 4: the class determines the strength of evidence, not whether registration is possible. The higher the class, the heavier the requirements for technical testing, inspection of manufacturing sites and clinical evidence. Every upward adjustment at the classification stage converts directly into cost and timeline.

Insight 5: the class also shapes how much of the dossier is scrutinized at each stage. Although № 177 applies circulation obligations without differentiating by class, the registration stage scales with the class: higher-tier devices attract heavier technical testing and, in the union system, stricter scrutiny of manufacturing sites and clinical evidence. Since № 211 simplifies the clinical evaluation only for devices of the low (first) potential risk level, the practical planning rule is straightforward: a classification conclusion one tier higher than necessary multiplies evidence work without adding market value. Classification should therefore be defended with documented reasoning, not assumed.

4. Practical recommendations

1. Do the classification work early and document it. Write the classification conclusion and the reasoning against the criteria into a one-page document as the input for the subsequent scope of testing and clinical strategy.
2. Classify general devices and IVD devices separately. Do not share one criteria template; IVD devices must follow their separate criteria.
3. Standardize terminology in external documents. Quotations, proposals and tender documents should uniformly use Class 1 / Class 2a / Class 2b / Class 3, with the original класс 1 / 2a / 2b / 3 in brackets.
4. Manage reclassification as a change trigger. When the intended use, contact mode or site of use of a product changes, reassess the class and, where necessary, process a change to the registration dossier.

5. Verification checklist

• □ Adopted the four-tier notation 1, 2a, 2b, 3; Class I/II/III notation not used
• □ Confirmed the classification rules rest on Decision № 173 of the Board of the Eurasian Economic Commission (2015-12-22)
• □ IVD devices classified under the separate criteria
• □ Classification reasoning documented in writing
• □ Reclassification mechanism triggered by intended-use changes established

Regulatory information verified as of 2026-10-30.

In the Eurasian Economic Union market, GRZAN concentrates its core capabilities in three areas. First, distinguishing between the union-wide registration route and each member state’s national registration route — their applicable conditions and remaining time windows. The national registration procedure of Belarus has been fully replaced by Council of Ministers Resolution No. 211 of 28 April 2026 (state registration number 6-1/55925, effective 1 May 2026), which caps the total duration of preliminary technical work at 90 calendar days, keeps the list of that work closed and prohibits the organizing body from expanding it, while the window for filing applications under the national procedure has 31 December 2027 as its key date, so the choice of route must be made in step with the time window. Second, local authorized representative services: GRZAN may act as the manufacturer’s statutory representative in Belarus, undertaking registration submissions, responses to technical queries, changes to the registration dossier and post-market reporting obligations, and it has updated its liaison arrangements after Council of Ministers Resolution No. 378 of 27 July 2026 (effective 30 July 2026) transferred the adverse-event functions to the State Institution State Medical Products Supervision (Gosfarmnadzor). Third, quality system and testing support: GRZAN assists in establishing a quality management system that meets ISO 13485 requirements and in organizing technical documentation for the chosen route — the national route follows the annexes to Ministry of Health Resolution No. 55, and the union route follows Decision No. 46 of the Board of the Eurasian Economic Commission.

Business inquiries: info@grzanglobal.com